Wells Fargo lowered the firm’s price target on Alnylam (ALNY) to $376 from $479 and keeps an Equal Weight rating on the shares. The firm raised FY26 Amvuttra estimates by 6% but its R&D expenses move up to about 30% of revenues between 2026-2030, compressing operating margins to management’s 30% guide vs. Street’s 40%-50%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Top 3 Trending Stocks, According to Analysts – 1/15/2026
- Alnylam: Near-Term Amvuttra Shortfall Outweighed by Robust TTR Growth Outlook and Strengthened Long-Term Leadership Position
- Alnylam Pharmaceuticals: Strong Long-Term Growth Strategy But Balanced Risk/Reward Supports Hold Rating
- Alnylam 2026 guidance reflects continued momentum, says H.C. Wainwright
- Alnylam price target raised to $529 from $520 at Needham